The Foundation for Sarcoidosis Research (FSR) marks 25 years of work to help people with sarcoidosis live better lives with an evening gala honoring leaders and partners driving research, care, and advocacy for the disease. Its 25th Anniversary Awards Gala — to be held Oct. 22 at…

Treatment with Atyr Pharma’s efzofitimod, known as EFZO-FIT for short, led to improvements in general health-related quality of life and reductions in fatigue for adults with pulmonary sarcoidosis taking part in a Phase 3 clinical trial, according to new data. Consistent with previously announced top-line results, these…

Treatment with rituximab can lead to meaningful improvements for some people with neurosarcoidosis affecting the brain and/or spinal cord — particularly those with hard-to-treat disease and involvement limited to some nerves. That’s according to a retrospective study of 19 people treated across four U.S. centers, which showed that…

Sitting at the infusion center for my intravenous immunoglobulin (IVIG) treatment, I opened up a Google Docs tab on my laptop. I’d just gotten an idea for a column, and wanted to jot down some notes before I forgot it. I had typed exactly eight words when another patient stopped…

Sarcoidosis is a chronic, multi-organ disease for most patients receiving care in specialty centers, and it has the potential to become more severe with time, according to a large U.S. study. Patients also had high rates of pulmonary fibrosis, or lung scarring, which is associated with worse lung function, and…

EFZO-FIT, a Phase 3 clinical study testing efzofitimod for pulmonary sarcoidosis, failed to meet its main goal of significantly reducing the need for corticosteroids among people with the rare inflammatory disease. However, the first-in-class immunomodulatory therapy did show some clinical benefits, according to its developer Atyr Pharma. Specifically,…

People with sarcoidosis who respond poorly to tumor necrosis factor inhibitors (TNFi) — used to treat the immune system disease when other therapies haven’t worked — frequently develop anti-drug antibodies (ADAs), which are linked to lower blood drug levels and likely affect treatment effectiveness. That’s according to a…

Four blood metabolites, or intermediate or end products of the body’s metabolism, could serve as noninvasive biomarkers to monitor or predict disease outcomes in people with pulmonary sarcoidosis — in which the lungs are primarily affected by this rare inflammatory disease — according to the results of a new study…

Black women with sarcoidosis have a risk of developing kidney stones that’s nearly twice as high as for people without the disease, a U.S. study suggests. The risk increased as the number of co-occurring metabolic conditions grew, including high blood pressure and high levels of fatty molecules in the…